Amaryl 3

Quick links to important sections

Amaryl 3

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amaryl 3

Quick Facts

Property Description
Active ingredient Glimepiride
Form Oral Tablet
Pharmacological class Sulfonylurea (Antidiabetic Agent)
Common use Management of Type 2 Diabetes Mellitus
Origin Synthetic Compound

What is Amaryl 3: Classification and Active Ingredient

Amaryl 3 is the trade name for the specific strength of the active substance Glimepiride, which is a synthetic, single-ingredient oral medication manufactured by Sanofi. Glimepiride is officially classified as a sulfonylurea and belongs to the therapeutic class of antidiabetic agents. The compound is often designated as a third-generation sulfonylurea, a distinction noting its action profile compared to older agents in the class. Glimepiride is primarily used to achieve blood glucose control in adults with Type 2 diabetes who do not respond adequately to diet and exercise alone. Consequently, Glimepiride’s role is to act as a systemic agent to address persistent high blood sugar. The numeric designation "3" in Amaryl 3 specifies the quantity of Glimepiride present, typically 3 milligrams, which is a crucial distinction from other available dosage strengths.


Form, Composition, and General Therapeutic Purpose

Amaryl 3 is provided as a prescription-only (Rx) oral tablet, which is the designated oral route of administration. The composition is entirely centered on the therapeutic compound Glimepiride, supported by essential inactive ingredients, or excipients, required for the tablet's integrity and correct systemic delivery. The general therapeutic purpose of Glimepiride is to provide effective blood glucose lowering for adults with Type 2 diabetes mellitus. Glimepiride's mechanism involves both stimulating the release of insulin from the pancreas and improving the sensitivity of peripheral tissues to insulin, an extrapancreatic effect. This dual action is fundamental to its role, allowing for glycemic management by helping the body both produce more insulin and utilize the available insulin more effectively.

Regulatory References

  1. Glimepirida Parke-Davis (EMA Referral)

What side effects are possible with Amaryl 3?

Possible Side Effects and Safety Information

The safety profile of Amaryl 3 (Glimepiride) is primarily structured by the risk of hypoglycaemia (low blood sugar), which is officially classified as a common adverse reaction in regulatory documents and represents the most significant safety concern for sulfonylureas. Other common effects may include headache, nausea, and dizziness.

Classification of Adverse Reactions

Adverse effects are categorized by the system-organ class (SOC) affected and their frequency, as defined by global regulatory bodies:

  • Metabolism and Nutrition Disorders frequently involve hypoglycaemia. Other documented effects include hyponatremia and weight gain.
  • Gastrointestinal Disorders such as vomiting, diarrhoea, and abdominal pain are noted, though generally classified as uncommon.
  • Rare adverse reactions include effects on the Blood and Lymphatic System, such as thrombocytopenia, leucopenia, and in very rare cases, severe blood dyscrasias like agranulocytosis or hemolytic anemia.
  • Very Rare effects involve Hepatobiliary Disorders (e.g., cholestasis, hepatitis) and severe hypersensitivity reactions, including Stevens-Johnson Syndrome (SJS) and anaphylaxis.

Safety Constraints and Special Populations

Official prescribing information outlines specific patient-based safety constraints. The risk of severe hypoglycaemia is elevated for older adults and patients with renal or hepatic impairment, often necessitating careful use. Furthermore, Glimepiride is formally contraindicated in patients with a history of hypersensitivity to the drug or to sulfonamide derivatives, and its use is restricted in conditions such as diabetic ketoacidosis. Temporary visual disturbance is noted to occur, particularly at the beginning of treatment, due to initial fluctuations in blood glucose levels.

This official safety documentation is critical for understanding the risk profile and constraints associated with Glimepiride.

Overdose and Emergency Response

The official regulatory profile for Amaryl 3 (Glimepiride) overdose is strictly defined by the risk of metabolic toxicity associated with its pharmacological class.

Overdose Manifestation Regulator-Mandated Action
Severe Hypoglycemia Seek Emergency Medical Attention Immediately

An overdosage of Glimepiride tablets is officially documented to produce severe hypoglycemia, which is the only clinical manifestation listed in regulatory prescribing information. This metabolic event is classified as potentially life-threatening due to the risk of prolonged neurological consequences and is considered the primary danger of overdose exposure.

Because of this severe presentation, it is mandated that users seek emergency medical attention immediately upon known or suspected overdose. Official regulatory guidance specifies that immediate procedural actions include contacting a Poison Help Line as part of the emergency response.

The supportive management of overdose is centered entirely on correcting the underlying metabolic imbalance. There is no specific chemical antidote listed in the official labeling. Treatment requires the administration of glucose or dextrose to rapidly correct the dangerously low blood sugar levels. Furthermore, regulatory documents require that patients undergo prolonged hospital observation and monitoring. This extended observation is necessary due to Glimepiride's long half-life, which creates a significant risk of recurring or relapsing hypoglycemia following the initial medical intervention.

Therapeutic Uses of Amaryl 3

What Amaryl 3 Treats: Main Uses and Benefits

Amaryl 3 is commonly used for managing the metabolic challenges of Type 2 Diabetes Mellitus in adults when diet, exercise, and weight reduction alone are not adequate. The primary benefit is its role in supporting long-term glycemic management, which may help maintain a sense of stability during symptomatic periods. The therapeutic relevance of Amaryl 3 involves managing persistently elevated blood glucose levels, helping to address the systemic imbalance of hyperglycemia, and supplementing foundational lifestyle changes.

This medication is generally considered relevant in conditions where patients present with suboptimal blood sugar control, meaning their metabolic goals are not met by foundational lifestyle changes. It helps manage the overall symptom burden associated with the disease and may assist with addressing symptom clusters that may become intense or disruptive. Amaryl 3 may be used in combination with other antidiabetic agents when the targeted blood glucose levels have not been reached by a single medication.

“This supportive action assists patients with managing the challenges of a chronic condition, supporting their efforts toward the long-term maintenance of their diabetes management plan.”


Quick Fact: Support for Persistent Hyperglycemia Amaryl 3 may be part of symptomatic management that supports a comprehensive approach to blood sugar lowering, contributing to the goal of achieving and sustaining targeted HbA1c levels, which helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Amaryl 3 is officially intended for use by adults with Type 2 Diabetes Mellitus. Eligibility for the medicine is defined by strict regulatory parameters that establish absolute contraindications and population-specific restrictions.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults with Type 2 Diabetes Mellitus.
Populations for whom use is contraindicated Type 1 Diabetes Mellitus; Diabetic Ketoacidosis (DKA); Hypersensitivity to Glimepiride or sulfonamide derivatives.
Age-related eligibility rules Use in Pediatric patients (under 18 years) is not established and not recommended.
Condition-specific eligibility rules Severe Renal or Hepatic Function Disorders are contraindications.
Pregnancy and lactation eligibility status Pregnancy is Contraindicated; Lactation is Not Recommended.

Resulting Eligibility Structure

Official eligibility statements:

  • Use is contraindicated in patients with Type 1 Diabetes, DKA, or known allergy to Glimepiride or sulfa drugs.
  • The medicine is not established and not recommended for children and adolescents.
  • Severe renal and hepatic function disorders prohibit use, necessitating a temporary switch to insulin.

Connection to the overall eligibility profile Regulatory documents define eligibility by setting absolute prohibitions for acute states and Type 1 Diabetes, as well as clear restrictions based on developmental status and organ health. Eligibility is generally reserved for adults with Type 2 Diabetes, with additional caution advised for older adults and those with G6PD deficiency.

What should I know about interactions with other medicines?

Amaryl (glimepiride) may interact with numerous other medicinal products, leading to either an undesired increase or decrease in its blood-glucose-lowering effect. Close monitoring and dose adjustment are typically required when taking Amaryl concurrently with other drugs.

Potential Interactions

Interaction Type Examples of Interacting Medicines or Classes
Potentiation of Effect (Risk of Hypoglycemia) Other oral anti-diabetic agents, insulin, NSAIDs, salicylates, MAOIs, fluconazole, clarithromycin, sulfonamides, ACE inhibitors, high-dose parenteral pentoxifylline.
Weakening of Effect (Risk of Hyperglycemia) Corticosteroids, thyroid hormones, estrogens, progestogens, phenothiazines, diuretics (thiazides), rifampicin, glucagon, somatropin, sympathomimetic agents.
Potentiate or Weaken Effect (Unpredictable) H2 antagonists, clonidine, reserpine, alcohol, coumarin derivatives (anticoagulants).

Specific Pharmacokinetic & Procedural Constraints

Amaryl is metabolized by the enzyme Cytochrome P450 2C9 (CYP2C9). Inhibitors of CYP2C9 (e.g., fluconazole) may increase glimepiride plasma concentrations, raising the risk of hypoglycemia, while inducers (e.g., rifampicin) may decrease concentrations, potentially worsening glycemic control. Co-administration of oral miconazole has been associated with reports of severe hypoglycemia.

To prevent reduced absorption, Amaryl must be administered at least 4 hours prior to taking the bile acid sequestrant colesevelam.

Hypoglycemia Awareness

Sympatholytic drugs, such as beta-blockers, clonidine, guanethidine, and reserpine, may reduce or mask the signs of adrenergic counter-regulation that typically alert a patient to hypoglycemia.

Mechanism of Action

Targeted Secretion: mathbfKATP Channel Blockade

Amaryl 3 (Glimepiride) acts primarily by engaging a key mechanism within the insulin-producing beta-cells of the pancreas. The molecule binds specifically to the Sulfonylurea Receptor 1 (SUR1) subunit on the ATP-sensitive potassium channel (mathbfKATP channel), causing the channel to close. This inhibition of potassium efflux initiates a precise molecular cascade involving membrane depolarization and subsequent Ca^2+ influx, which serves to initiate the exocytosis of insulin into the circulation.

Dual Action: Enhancing Peripheral and Hepatic Control

Beyond stimulating insulin release, Glimepiride also modulates the systemic utilization of glucose. It has an important extrapancreatic effect that increases the sensitivity of peripheral tissues, such as muscle and fat, to the effects of insulin. Concurrently, the resulting increase in circulating insulin acts on the liver to dampen the rate of endogenous glucose production. These complementary actions enhance glucose disposal and suppress its internal supply, leading to a systemic modulation of glucose concentration.

Dosage and Administration Information

Administration Guidelines for Amaryl 3 (Glimepiride)

The usage of Amaryl 3 follows precise, standardized protocols. The medication is an oral tablet and is administered once daily.

Dosage and Scheduling

The treatment protocol begins with a low initial dose of 1 mg or 2 mg once daily. The maximum daily dose typically ranges from 6 mg to 8 mg.

Instruction Detail
Timing in Relation to Meals Administer with breakfast or the first main meal of the day.
Titration Schedule Dose adjustments are made in 1 mg or 2 mg increments, but no more frequently than every 1 to 2 weeks baker.
Missed Dose Rule A forgotten dose must not be corrected by subsequently taking a larger dose.

Administration Requirements

Adherence to timing and specific patient population considerations is required. The tablets may be divided into halves, which supports flexibility in dose adjustment. For certain patient groups, a conservative starting dose of 1 mg once daily is utilized for older adults and those with renal impairment. Additionally, for patients who are also taking colesevelam (a bile acid sequestrant), Glimepiride must be administered at least 4 hours prior to colesevelam to ensure adequate absorption. This procedural step is essential to maintain the proper use of the medication.

Recent Clinical Evidence

Amaryl 3: Recent Clinical Evidence

Evidence for Glycemic Control in Type 2 Diabetes

Glimepiride was studied for its use in adults with Type 2 Diabetes Mellitus who have difficulty addressing blood sugar levels through diet and exercise alone. Research has primarily examined its use as a single treatment (monotherapy) and as an add-on therapy alongside other diabetes medications. The core evidence comes from Randomized Controlled Trials (RCTs) and systematic reviews that explored how metabolic biomarkers shift during treatment. These trials evaluated Glycated Hemoglobin ( HbA1c) and Fasting Plasma Glucose (FPG).

However, the research highlights that these findings focus mainly on surrogate endpoints like HbA1c, which are markers for average blood sugar. Long-term outcomes are not fully established by these initial trials, and evidence related to long-term complication outcomes is not fully established.

Long-Term Research and Macrovascular Outcomes

Glimepiride was evaluated in large-scale, long-term comparative trials that research has explored to assess its relationship with major clinical outcomes, specifically those affecting the cardiovascular system. Studies monitored outcomes such as the occurrence of Major Adverse Cardiovascular Events (MACE) over observation periods that often extended for five to six years.

What remains uncertain is the conclusive evidence of whether Glimepiride is associated with a definitive change in macrovascular risk. Official research reports suggest that no dedicated clinical studies have definitively established this observation. Furthermore, research conducted does not provide a basis for claiming comparative advantage related to major cardiovascular endpoints.

Evidence in Specific Patient Groups

Research has explored the use of Glimepiride in various specific patient groups. Dedicated studies were conducted to evaluate the measured changes in older adults (geriatric patients). Studies also examined Glimepiride in patients who were newly starting medication (treatment-naive). However, findings for certain subgroups remain uncertain, and data for certain special groups remain insufficient.

Key Studies & References

  1. GLIMEPIRIDE - DailyMed: Clinical Studies, Use in Specific Populations, and Warnings

Frequently Asked Questions (FAQ)

Common questions about Amaryl 3 (FAQ)

Q: What does the number '3' mean in Amaryl 3?

The number '3' in Amaryl 3 specifies the dosage strength of the active ingredient, Glimepiride. This means the tablet contains 3 milligrams (mg) of Glimepiride. Official product information confirms that other strengths are also available, which are distinguished by different numbers in the drug name.

Q: Is Amaryl 3 safe for people with kidney problems?

Regulatory guidance addresses the use of Amaryl 3 in people with kidney conditions. Official guidance indicates that dose adjustments may be necessary for patients with renal impairment. Use is contraindicated (not allowed) in cases involving severe renal function disorders.

Q: Can Amaryl 3 be used by older adults?

Official documents describe that Amaryl 3 can be used by older adults (geriatric patients). However, due to a reported risk of prolonged low blood sugar (hypoglycemia), official documents advise that treatment initiation and adjustment for this population should be managed carefully.

Q: Can using alcohol affect Amaryl 3?

Yes, official warnings note that consuming alcohol when taking Glimepiride has an unpredictable effect on blood glucose levels. This interaction may be associated with either dangerously low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia).

Q: Is Amaryl 3 considered a first-line treatment for diabetes?

The official indication for Amaryl 3 is the management of Type 2 Diabetes Mellitus. It is approved for use when blood sugar levels are not adequately controlled by diet and exercise alone. It can be prescribed as the only diabetes medication (monotherapy) or combined with others.

Q: Can Amaryl 3 be stopped suddenly?

Regulatory guidance suggests that cessation of the medication is recommended to occur under medical supervision. Abrupt stopping may be associated with a loss of blood glucose control, resulting in high blood sugar (hyperglycemia).

Q: Does Amaryl 3 interact with birth control pills?

Official regulatory documents state that hormonal birth control pills (containing estrogens or progestogens) may weaken the blood-sugar-lowering effect of Amaryl 3. This may be associated with an increased risk of high blood sugar (hyperglycemia).

Q: Does Amaryl 3 contain a steroid?

No, Amaryl 3 is not a steroid. It is officially classified as a sulfonylurea, which is a type of antidiabetic agent. The composition of the tablet is based solely on the active ingredient, Glimepiride, and necessary inactive components.

Q: Is Amaryl 3 a type of insulin?

No. Amaryl 3 is classified as a sulfonylurea, which is a class of antidiabetic agents that works by stimulating the body's own pancreas to release insulin. It is not a form of insulin replacement.

Q: How quickly does Amaryl 3 start to work?

Clinical studies indicate that the substance reaches its peak concentration in the bloodstream typically within 2 to 3 hours after administration. This pharmacokinetic information is used to help inform dosing schedules.

Q: Is Amaryl 3 known to cause weight gain?

Yes, official safety information lists weight gain as a reported adverse reaction. This is categorized under disorders related to metabolism and nutrition in regulatory documents.

Q: What are the most common side effects of Amaryl 3?

The most significant reported safety concern is hypoglycemia (low blood sugar), which is officially classified as a very common adverse reaction. Other common side effects reported include headache, dizziness, and nausea.

Q: Can Amaryl 3 affect my liver function?

Official safety data lists very rare adverse effects on the liver, which include disorders such as cholestasis and hepatitis. For this reason, regulatory guidelines note the importance of the regular monitoring of liver function.

Q: Does Amaryl 3 interact with pain relievers like ibuprofen?

Yes, official regulatory documents note that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as common pain relievers like ibuprofen, may increase the blood-sugar-lowering effect of Amaryl 3. This may raise the potential for low blood sugar (hypoglycemia).

Q: What is the difference between Amaryl 3 and Amaryl 2?

The distinction between Amaryl 3 and Amaryl 2 is the dosage strength of the active ingredient, Glimepiride. Amaryl 3 contains 3 mg, while Amaryl 2 contains 2 mg of Glimepiride.

Q: Is Amaryl 3 a generic medication?

Amaryl is a brand name product. The active pharmaceutical ingredient, Glimepiride, is the compound contained in the tablet, and Glimepiride is widely available as a generic medication from various manufacturers.

Q: Does Amaryl 3 have a Black Box Warning?

The regulatory label for Glimepiride in the United States does not contain an FDA-mandated Boxed Warning (colloquially referred to as a Black Box Warning).

Q: Is it possible to become resistant to Amaryl 3 over time?

Yes. Official documents acknowledge the potential for secondary failure. This is described as a gradual loss of the drug's ability to maintain adequate blood sugar control after an initial period where the medicine was effective.

Q: What happens if I accidentally take too much Amaryl 3?

Overdose is officially associated with the risk of severe low blood sugar (hypoglycemia). Emergency medical treatment is required to address this event.

Q: Does Amaryl 3 cause increased risk of heart issues?

Regulatory documents note that Glimepiride belongs to the sulfonylurea class. Early research on this drug class examined a potential increased risk of death due to cardiovascular issues compared to treatment with diet alone or diet plus insulin.

Q: Is Amaryl 3 approved for use in children?

The official documents state that the efficacy and safety of Glimepiride have not been established in children and adolescents. Therefore, its use in the pediatric population is not recommended by regulatory bodies.

Q: How often do I need blood tests while on Amaryl 3?

Regulatory documents note the importance of monitoring blood and urine glucose levels. Additionally, periodic determination of the long-term blood sugar marker, glycated hemoglobin (HbA1c), is recommended.

Q: Is Amaryl 3 suitable for pre-diabetes?

No. The official regulatory indications state that Amaryl 3 is approved only for the management of Type 2 Diabetes Mellitus. It is not indicated for use in individuals with pre-diabetes.

Q: What is the typical time frame for seeing the full effects of Amaryl 3?

Official administration instructions recommend that dose adjustments be made no more frequently than every one to two weeks. The dose adjustment schedule suggests that up to two weeks may be needed to assess the full effect of any dose change on blood glucose.

Q: Do studies show Amaryl 3 helps with long-term diabetes management?

Official research summaries confirm that studies demonstrate Glimepiride's effect on surrogate markers like Glycated Hemoglobin (HbA1c). However, regulatory sources conclude that evidence regarding its effect on long-term complication outcomes remains uncertain.

Q: Can Amaryl 3 be taken with blood pressure medication?

Yes, but there is a potential for interaction. Official labels list several blood pressure medication classes, such as ACE inhibitors and diuretics. These interactions may necessitate careful blood glucose monitoring and potential adjustments to the prescribed treatment.

Q: Are there any skin reactions associated with Amaryl 3?

Yes, official safety data notes several reported skin reactions, including pruritus (itching) and various forms of rashes. In very rare instances, severe hypersensitivity reactions such as Stevens-Johnson Syndrome (SJS) have also been reported.

Q: Is it normal to feel dizzy or tired when taking Amaryl 3?

Official safety documents list dizziness as a common side effect. Fatigue or tiredness is also listed among the possible reported adverse effects.

Q: Can Amaryl 3 cause changes in vision?

Official safety information notes the possibility of temporary visual disturbance. This is primarily observed at the start of treatment and is linked to the initial fluctuations in blood glucose levels as the body adjusts.

Q: Can I take herbal supplements while using Amaryl 3?

Official label information advises patients to inform their healthcare provider of all herbal products and non-prescription medicines, as some may interact and affect blood sugar levels.

Q: Why do official documents mention Amaryl 3 and cardiovascular risk?

This information is included because the drug belongs to the sulfonylurea drug class. Official warnings are mandated due to specific early research that examined a potential increased risk of cardiovascular mortality linked to this class.

Q: Is Amaryl 3 effective if I also make lifestyle changes?

Yes. The medicine is officially indicated for use as an addition to diet and exercise to improve blood sugar control.

Q: Can Amaryl 3 cause or worsen depression?

Official regulatory labels include depression as one of the reported adverse reactions. This effect is generally categorized as being of unknown or rare frequency.

Q: Does Amaryl 3 affect cholesterol levels?

Evidence from specific clinical studies examined in regulatory reviews suggests Glimepiride may be associated with an increase in high-density lipoprotein cholesterol (HDL-c) levels in some patients.

Q: Are there known issues with driving or operating machinery while taking Amaryl 3?

Yes. Due to the inherent risk of low blood sugar (hypoglycemia), which can impair concentration and slow reaction time, official warnings advise that this condition may impact the ability to drive or operate machinery.

Q: Does Amaryl 3 have a high risk of drug-drug interactions?

Official labeling contains an extensive section listing numerous drug classes that can interact with Glimepiride. This indicates a potential for drug-drug interactions, which can either increase or decrease the drug's primary effect.

Q: Can Amaryl 3 affect my appetite?

Official adverse reaction lists note changes to appetite as a possible effect. This includes both the experience of a loss of appetite and sometimes increased hunger (which can be a symptom of low blood sugar).

How should Amaryl 3 be stored and disposed of?

Official Storage and Disposal Guidelines

Amaryl 3 (glimepiride) tablets must be stored according to regulatory requirements to ensure stability and proper handling. The medication must be maintained at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must not be stored above 30 C.

Storage and Handling

  • Environmental Protection: Keep the tablets in their original packaging, stored tightly closed, and protected from excessive heat and moisture.
  • Child Safety: It is mandatory to store Amaryl out of the sight and reach of children.

Disposal

Official guidelines recommend disposing of unused or expired Amaryl through a drug take-back program. If this is unavailable, the product should be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag, and discarded in the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amaryl 3 found in:

A-Z Index: